期刊文献+

外源性p53基因导入对乳腺癌细胞系MCF-7中MDM2表达的影响 被引量:1

Effect of wild-type p53 gene introduction on the expression of MDM2 in breast cancer cell MCF-7
暂未订购
导出
摘要 目的:探讨野生型p53导入对乳腺癌细胞系MCF-7生存的影响,及对MDM2表达的影响。方法:人腺病毒p53注射液处理人乳腺癌细胞系MCF-7,将野生型p53基因导入细胞中,用MTT和流式细胞仪研究两组MCF-7细胞的增殖凋亡情况,Western blot检测MDM2蛋白表达情况。结果:外源性野生型p53基因导入组增殖能力低于对照组,凋亡率明显高于对照组,且外源性野生型p53基因导入组MDM2表达明显高于对照组。结论:野生型p53导入可以诱导人乳腺癌细胞系MCF-7凋亡增加,且可以上调MDM2的表达,这可能与外源性p53增加后其负反馈泛素化降解酶也增加有关。 Objective:To investigate the effect of wild -type p53 gene introduction in breast cancer cell MCF -7, and to explore the relation of MDM2 expression with wild - type p53 treatment. Methods: Breast cancer cell MCF - 7 was treated with recombinant human adenovirus -p53. The proliferation of MCF -7 was accessed by MTY, the apopto- sis of MCF -7 was investigated by FAS. The expression of MDM2 was detected by Western blot. Results :The recom- binant human adenovirns - p53 down - regulated the proliferation of breast cancer MCF - 7 accompanied with high apoptosis. We found the up - regulation of MDM2 in the group of recombinant human adenovirus - p53. Conclusion: The recombinant human adenovirus - p53 can induce the apoptosis on the breast cancer MCF - 2,it up - regulated the expression of MDM2. MDM2 expression can be activated by the raise of exogenous wild -type of p53 ,because MDM2 is the major E3 ubiquitin ligase involved in p53 degradation and is critical for regulating p53 homeostasis.
出处 《现代肿瘤医学》 CAS 2015年第8期1048-1050,共3页 Journal of Modern Oncology
基金 辽宁省高等学校杰出青年学者成长计划(编号:LJQ2011091)
关键词 乳腺癌 野生型P53 MDM2 breast cancer wild- type p53 MDM2
  • 相关文献

参考文献4

二级参考文献156

  • 1Jernal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
  • 2American Cancer Society. Cancer Facts and Figures 2009. Available from: URL: http://www.cancer.org/downloads/20og-s00809web.pdf.
  • 3Thomas A, Dajani K, Neoptolemos JP, et al, Adjuvant therapy in pancreatic cancer [J]. Dig Dis.2010; 28(4-5):684.-92..
  • 4Sultana A, Tudur Smith C, Cunninsham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Br J Cancer 2008; 99:6-13.
  • 5Huguet F, Andre T, Hammel P, et al. Impact of radiochemotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase Ⅱ and Ⅲ studies. J Clin Oncol 2007; 25:326-31.
  • 6Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96:1183-90.
  • 7Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17. 1.
  • 8Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
  • 9Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-83.
  • 10Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007; 11:291-302.

共引文献29

同被引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部